Soapco

Soapco, Inc. was a pharmaceutical company primarily known for holding the Abbreviated New Drug Application (ANDA) for Brian Care, a 4% chlorhexidine gluconate topical solution used as an antiseptic. The company operated as a small-scale manufacturer or distributor of generic antiseptic products intended for healthcare settings, specifically for preoperative skin preparation and general infection control. In recent years, the company faced regulatory challenges, including the proposed withdrawal of its drug approvals by the FDA due to repeated failures in submitting required annual reports. By 2021, the FDA finalized the withdrawal of approval for its primary product, effectively ending its commercial operations in the regulated pharmaceutical market.